# A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.

> **NCT07490262** · PHASE2,PHASE3 · RECRUITING · sponsor: **Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.** · enrollment: 680 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin
- **BIOLOGICAL:** IBI310
- **BIOLOGICAL:** Sintilimab

## Key facts

- **NCT ID:** NCT07490262
- **Lead sponsor:** Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-27
- **Primary completion:** 2027-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 680 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07490262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07490262, "A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07490262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*